Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Jan 31;2013(1):CD009671.
doi: 10.1002/14651858.CD009671.pub2.

Selenium supplementation for the primary prevention of cardiovascular disease

Karen Rees  1 , Louise Hartley, Camilla Day, Nadine Flowers, Aileen Clarke, Saverio Stranges
Affiliations
Meta-Analysis

Selenium supplementation for the primary prevention of cardiovascular disease

Karen Rees et al. Cochrane Database Syst Rev. .

Abstract

Background: Selenium is a key component of a number of selenoproteins which protect against oxidative stress and have the potential to prevent chronic diseases including cardiovascular disease (CVD). However, observational studies have shown inconsistent associations between selenium intake and CVD risk; in addition, there is concern around a possible increased risk of type 2 diabetes with high selenium exposure.

Objectives: To determine the effectiveness of selenium only supplementation for the primary prevention of CVD and examine the potential adverse effect of type 2 diabetes.

Search methods: The following electronic databases were searched: the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 10 of 12, October 2012) on The Cochrane Library; MEDLINE (Ovid) (1946 to week 2 October 2012); EMBASE Classic + EMBASE (Ovid) (1947 to 2012 Week 42); CINAHL (EBSCO) (to 24 October 2012); ISI Web of Science (1970 to 24 October 2012); PsycINFO (Ovid) (1806 to week 3 October 2012); Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database and Health Economics Evaluations Database (Issue 4 of 4, October 2012) on The Cochrane Library. Trial registers and reference lists of reviews and articles were searched and experts in the field were approached. No language restrictions were applied.

Selection criteria: Randomised controlled trials on the effects of selenium only supplementation on major CVD end-points, mortality, changes in CVD risk factors, and type 2 diabetes were included both in adults of all ages from the general population and in those at high risk of CVD. Trials were only considered where the comparison group was placebo or no intervention. Only studies with at least three months follow-up were included in the meta-analyses, shorter term studies were dealt with descriptively.

Data collection and analysis: Two review authors independently assessed trial quality and extracted data. Study authors were contacted for additional information.

Main results: Twelve trials (seven with duration of at least three months) met the inclusion criteria, with 19,715 participants randomised. The two largest trials that were conducted in the USA (SELECT and NPC) reported clinical events. There were no statistically significant effects of selenium supplementation on all cause mortality (RR 0.97, 95% CI 0.88 to 1.08), CVD mortality (RR 0.97, 95% CI 0.79 to 1.2), non-fatal CVD events (RR 0.96, 95% CI 0.89 to 1.04) or all CVD events (fatal and non-fatal) (RR 1.03, 95% CI 0.95 to 1.11). There was a small increased risk of type 2 diabetes with selenium supplementation but this did not reach statistical significance (RR 1.06, 95% CI 0.97 to 1.15). Other adverse effects that increased with selenium supplementation, as reported in the SELECT trial, included alopecia (RR 1.28, 95% CI 1.01 to 1.62) and dermatitis grade 1 to 2 (RR 1.17, 95% CI 1.0 to 1.35). Selenium supplementation reduced total cholesterol but this did not reach statistical significance (WMD - 0.11 mmol/L, 95% CI - 0.3 to 0.07). Mean high density lipoprotein (HDL) levels were unchanged. There was a statistically significant reduction in non-HDL cholesterol (WMD - 0.2 mmol/L, 95% CI - 0.41 to 0.00) in one trial of varying selenium dosage. None of the longer term trials examined effects on blood pressure. Overall, the included studies were regarded as at low risk of bias.

Authors' conclusions: The limited trial evidence that is available to date does not support the use of selenium supplements in the primary prevention of CVD.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1
1
Study flow diagram.
1.1
1.1. Analysis
Comparison 1 Selenium supplementation versus no intervention, Outcome 1 Total Cholesterol (mmol/l), change from baseline.
1.2
1.2. Analysis
Comparison 1 Selenium supplementation versus no intervention, Outcome 2 HDL Cholesterol (mmol/l), change from baseline.
1.3
1.3. Analysis
Comparison 1 Selenium supplementation versus no intervention, Outcome 3 Non‐HDL Cholesterol (mmol/l), change from baseline.
1.4
1.4. Analysis
Comparison 1 Selenium supplementation versus no intervention, Outcome 4 LDL Cholesterol (mmol/l), change from baseline.
1.5
1.5. Analysis
Comparison 1 Selenium supplementation versus no intervention, Outcome 5 Triglycerides (mmol/l), change from baseline.
1.6
1.6. Analysis
Comparison 1 Selenium supplementation versus no intervention, Outcome 6 All cause mortality.
1.7
1.7. Analysis
Comparison 1 Selenium supplementation versus no intervention, Outcome 7 CVD mortality.
1.8
1.8. Analysis
Comparison 1 Selenium supplementation versus no intervention, Outcome 8 All CVD events (fatal and non fatal).
1.9
1.9. Analysis
Comparison 1 Selenium supplementation versus no intervention, Outcome 9 Non fatal CVD events.
1.10
1.10. Analysis
Comparison 1 Selenium supplementation versus no intervention, Outcome 10 Non fatal strokes.
1.11
1.11. Analysis
Comparison 1 Selenium supplementation versus no intervention, Outcome 11 Type 2 diabetes.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Algotar 200μg 2010 {published data only}
    1. Algotar AM, Stratton MS, Stratton PS, Hsu CH, Ahmann FR. No effect of selenium supplementation on serum glucose levels in men with prostate cancer. American Journal of Medicine 2010;123(8):765‐8. - PMC - PubMed
Algotar 2010 {published data only}
    1. Algotar AM, Stratton MS, Stratton PS, Hsu CH, Ahmann FR. No effect of selenium supplementation on serum glucose levels in men with prostate cancer. American Journal of Medicine 2010;123(8):765‐8. - PMC - PubMed
Algotar 800μg 2010 {published data only}
    1. Algotar AM, Stratton MS, Stratton PS, Hsu CH, Ahmann FR. No effect of selenium supplementation on serum glucose levels in men with prostate cancer. American Journal of Medicine 2010;123(8):765‐8. - PMC - PubMed
Hawkes 2008 {published and unpublished data}
    1. Hawkes WC, Laslett LJ. Selenium supplementation does not improve vascular responsiveness in healthy North American men. American Journal of Physiology‐Heart and Circulatory Physiology 2009;296(2):H256‐62. - PubMed
Luoma 1984 {published data only}
    1. Luoma PV, Korpela H, Sotaniem EA, Kumpulainen J. Serum selenium, glutathione peroxidase, lipids, and human liver microsomal enzyme activity. A double‐blind controlled trial of selenium supplementation. Biological Trace Element Research 1985;8:113‐121. - PubMed
    1. Luoma PV, Sotaniemi EA, Korpela H, Kumpulainen J. Serum selenium, glutathione peroxidase activity and high‐density cholesterol ‐ Effect of selenium supplementation. Research Communications in Chemical Pathology and Pharmacology 1984;46(3):469‐72. - PubMed
Meltzer 1994 {published data only}
    1. Meltzer HM, Mundal HH, Alexander J, Bibow K, Ydersbond TA. Does dietary arsenic and mercury affect cutaneous bleeding time and blood lipids in humans?. Biological Trace Element Research 1994;46:135‐53. - PubMed
Meltzer 1997 {published data only}
    1. Meltzer HM, Folmer M, Wang S, Lie O, Maage A, Mundal HH, Ydersbond TA. Supplementary selenium influences the response to fatty acid‐induced oxidative stress in humans. Biological Trace Element Research 1997;60:51‐68. - PubMed
Navas‐Carretero 2011 {published data only}
    1. Navas‐Carretero S, Cuervo M, Abete I, Zulet MA, Martínez JA. Frequent consumption of selenium‐enriched chicken meat by adults causes weight loss and maintains their antioxidant status. Biological Trace Element Research 2011;143:8‐19. [DOI: 10.1007/s12011-010-8831-x] - DOI - PubMed
NCP {published data only}
    1. Stranges S, Marshall JR, Trevisan M, Natarajan R, Donahue RP, Combs GF, et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine 2007;147(4):217‐23. - PubMed
    1. Stranges S, Marshall JR, Trevisan M, Natarajan R, Donahue RP, Combs GF, et al. Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomized clinical trial. American Journal of Epidemiology 2006;163(8):694‐9. - PubMed
Ravn‐Haren 2008 {published data only}
    1. Ravn‐Haren G, Bugel S, Krath BN, Hoac T, Stagsted J, Jorgensen K, et al. A short‐term intervention trial with selenate, selenium‐enriched yeast and selenium‐enriched milk: effects on oxidative defence regulation. British Journal of Nutrition 2008;99(4):883‐92. - PubMed
SELECT {published data only}
    1. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306(14):1549‐56. - PMC - PubMed
    1. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers. The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301(1):39‐51. - PMC - PubMed
UK PRECISE {published data only}
    1. Rayman MP, Blundell‐Pound G, Pastor‐Barriuso R, Guallar E, Steinbrenner H, Stranges S. A randomized trial of selenium supplementation and risk of type‐2 diabetes, as assessed by plasma adiponectin. PLoS ONE 2012;7(9):e45269. [DOI: 10.1371/journal.pone.0045269] - DOI - PMC - PubMed
    1. Rayman MP, Stranges S, Griffin BA, Pastor‐Barriuso R, Guallar E. Effect of supplementation with high‐selenium yeast on plasma lipids. A randomized trial. Annals of Internal Medicine 2011;154:656‐65 (Appendix W‐236‐40). - PubMed
UK PRECISE 100μg {published data only}
    1. Rayman MP, Stranges S, Griffin BA, Pastor‐Barriuso R, Guallar E. Effect of supplementation with high‐selenium yeast on plasma lipids. A randomized trial. Annals of Internal Medicine 2011;154:656‐65 (Appendix W‐236‐40). - PubMed
UK PRECISE 200μg {published data only}
    1. Rayman MP, Stranges S, Griffin BA, Pastor‐Barriuso R, Guallar E. Effect of supplementation with high‐selenium yeast on plasma lipids. A randomized trial. Annals of Internal Medicine 2011;154:656‐65 (Appendix W‐236‐40). - PubMed
UK PRECISE 300μg {published data only}
    1. Rayman MP, Stranges S, Griffin BA, Pastor‐Barriuso R, Guallar E. Effect of supplementation with high‐selenium yeast on plasma lipids. A randomized trial. Annals of Internal Medicine 2011;154:656‐65 (Appendix W‐236‐40). - PubMed
Wu 2009 {published data only}
    1. Wu J, Salisbury C, Graham R, Lyons G, Fenech. Increased consumption of wheat biofortified with selenium does not modify biomarkers of cancer risk, oxidative stress, or immune function in healthy Australian males. Environmental & Molecular Mutagenesis 2009;50(6):489‐501. - PubMed
Wu BIOFORT 2009 {published data only}
    1. Wu J, Salisbury C, Graham R, Lyons G, Fenech. Increased consumption of wheat biofortified with selenium does not modify biomarkers of cancer risk, oxidative stress, or immune function in healthy Australian males. Environmental & Molecular Mutagenesis 2009;50(6):489‐501. - PubMed
Wu PROFORT 2009 {published data only}
    1. Wu J, Salisbury C, Graham R, Lyons G, Fenech. Increased consumption of wheat biofortified with selenium does not modify biomarkers of cancer risk, oxidative stress, or immune function in healthy Australian males. Environmental & Molecular Mutagenesis 2009;50(6):489‐501. - PubMed
Yu 1990 {published data only}
    1. Yu SY, Mao BL, Xiao P, Yu WP, Wang YL, Huang CZ, et al. Intervention trial with selenium for the prevention of lung cancer among tin miners in Yunnan, China. A pilot study. Biological Trace Element Research 1990;24(2):105‐8. - PubMed

References to studies excluded from this review

Alfthan 1991 {published data only}
    1. Alfthan G, Aro A, Arvilommi H, Huttunen JK. Selenium metabolism and platelet glutathione peroxidase activity in healthy Finnish men: Effects of selenium yeast, selenite, and selenate. American Journal of Clinical Nutrition 1991;53(1):120‐5. - PubMed
Asfour 2006 {published data only}
    1. Asfour IA, El SS, Fayek MH, Hegab HM, Raouf S, Moussa MA. Effect of high‐dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non‐Hodgkin's lymphoma patients. Biological Trace Element Research 2006;110(1):19‐32. - PubMed
Karp 2010 {published data only}
    1. Karp DD, Lee SJ, Shaw Wright GL, Johnson DH, Johnston MR, Goodman GE, et al. A phase III, intergroup, randomized, double‐blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non‐small cell lung cancer (NSCLC). Journal of Clinical Oncology 2010;28(18 Suppl):CRA7004. - PMC - PubMed
Kruger 1998 {published data only}
    1. Kruger HS, Veldman FJ, Vorster HH, Vermaak WJH, Barnard HC. Combination anti‐oxidant supplement increases resistance of low‐density lipoprotein to oxidation and improves lipoprotein profile of hypercholesterolaemic men. South African Medical Journal 1998;88(5):646‐52.
Linxian trials {published data only}
    1. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease‐specific mortality in the general population. Journal of the National Cancer Institute 1993;85(18):1483‐92. - PubMed
    1. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey SM, Li B. The Linxian trials: mortality rates by vitamin‐mineral intervention group. American Journal of Clinical Nutrition 1995;62(6):1424S‐6S. - PubMed
    1. Li JY, Taylor PR, Li B, Dawsey S, Wang GQ, Ershow AG, et al. Nutrition intervention trials in Linxian, China: Multiple vitamin/mineral supplementation, cancer incidence, and disease‐specific mortality among adults with esophageal dysplasia. Journal of the National Cancer Institute 1993;85(18):1492‐8. - PubMed
Mundal 1994 {published data only}
    1. Mundal HH, Meltzer HM, Aursnes I. Bleeding times related to serum triglyceride levels in healthy young adults. Thrombosis Research 1994;75(3):285‐91. - PubMed
Mutanen 1989 {published data only}
    1. Mutanen M, Viita L, Mykkanen HM. Selenium supplementation does not alter platelet activation in subjects with normal selenium status. Vitamin & Nutrition Research 1989;59(3):309‐13. - PubMed
Ravn‐Haren 2008b {published data only}
    1. Ravn‐Haren G, Krath BN, Overvad K, Cold S, Moesgaard S, Larsen EH, et al. Effect of long‐term selenium yeast intervention on activity and gene expression of antioxidant and xenobiotic metabolising enzymes in healthy elderly volunteers from the Danish Prevention of Cancer by Intervention by Selenium (PRECISE) pilot study. British Journal of Nutrition 2008;99(6):1190‐8. - PubMed
SU.VI.MAX {published data only}
    1. Czernichow S, Couthouis A, Bertrais S, Vergnaud A, Dauchet L, Galan P, Hercberg S. Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. American Journal of Clinical Nutrition 2006;84(2):395‐9. - PubMed
    1. Czernichow S, Vergnaud AC, Galan P, Arnaud J, Favier A, Faure H, et al. Effects of long‐term antioxidant supplementation and association of serum antioxidant concentrations with risk of metabolic syndrome in adults. American Journal of Clinical Nutrition 2009;90(2):329‐35. - PubMed
    1. Hercberg S, Bertrais S, Czernichow S, Noisette N, Galan P, Jaouen A, et al. Alterations of the lipid profile after 7.5 years of low‐dose antioxidant supplementation in the SU.VI.MAX study. Lipids 2005;40(4):335‐42. - PubMed
    1. Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, et al. The SU.VI.MAX study: A randomized, placebo‐controlled trial of the health effects of antioxidant vitamins and minerals. Archives of Internal Medicine 2004;164(21):2335‐42. - PubMed
    1. Hercberg S, Preziosi P, Briancon S, Galan P, Triol I, Malvy D, et al. A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: The SU.Vi.Max study ‐ Design, methods, and participant characteristics. Controlled Clinical Trials 1998;19(4):336‐51. - PubMed
Wolters 2003 {published data only}
    1. Wolters M, Hahn A. Plasma ubiquinone status and response to six‐month supplementation combined with multivitamins in healthy elderly women ‐ Results of a randomized, double‐blind, placebo‐controlled study. International Journal for Vitamin and Nutrition Research 2003;73(3):207‐14. - PubMed

Additional references

Alanne 2007
    1. Alanne M, Kristiansson K, Auro K, Silander K, Kuulasmaa K, Peltonen L, et al. Variation in the selenoprotein S gene locus is associated with coronary heart disease and ischemic stroke in two independent Finnish cohorts.. Hum Genet 2007;122:355‐65. - PubMed
Blankenberg 2003
    1. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, et al. AtheroGene Investigators. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. New England Journal of Medicine 2003;349:1605‐13. - PubMed
Bleys 2007
    1. Bleys J, Navas‐Acien A, Guallar E. Serum selenium and diabetes in U.S. Adults. Diabetes Care 2007;30:829‐34. - PubMed
Bleys 2008
    1. Bleys J, Navas‐Acien A, Guallar E. Serum Selenium levels and all‐cause, cancer and cardiovascular mortality among US adults. Archives of Internal Medicine 2008;168:404‐10. - PubMed
Bleys 2009
    1. Bleys J, Navas‐Acien A, Laclaustra M, Pastor‐Barriuso R, Menke A, Ordovas JM, et al. Serum selenium and peripheral arterial disease: Results from the National Health and Nutrition Examination Survey (NHANES) 2003 ‐ 2004. American Journal of Epidemiology 2009;169:996‐1003. - PMC - PubMed
Brigelius‐Flohe 2003
    1. Brigelius‐Flohe R, Banning A, Schnurr K. Selenium‐dependent enzymes in endothelial function. Antioxidants & Redox Signaling 2003;5:205‐15. - PubMed
Broadley 2006
    1. Broadley MR, White PJ, Bryson RJ, Meacham MC, Bowen HC, Johnson SE, et al. Biofortification of UK food crops with selenium. Proceedings of the Nutrition Society 2006;65:169‐81. - PubMed
Brookes 2004
    1. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup‐specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology 2004;57:229‐36. - PubMed
Brown 2001
    1. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New England Journal of Medicine 2001;345:1583‐92. - PubMed
Burk 2002
    1. Burk RF. Selenium, an antioxidant nutrient. Nutrition in Clinical Care 2002;5:75‐9. - PubMed
Burk 2006
    1. Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW. Effects of chemical form of selenium on plasma biomarkers in a high‐dose human supplementation trial. Cancer Epidemiology, Biomarkers & Prevention 2006;15:804‐10. - PubMed
Combs 1998
    1. Combs GF Jr, Gray WP. Chemopreventive agents: selenium. Pharmacology & Therapeutics 1998;79:179‐92. - PubMed
Copeland 1977
    1. Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. American Journal of Epidemiology 1977;105:488‐95. - PubMed
Curran 2005
    1. Curran JE, Jowett JB, Elliott KS, Gao Y, Gluschenko K, Wang J, et al. Genetic variation in selenoprotein S influences Inflammatory response. Nature Genetics 2005;37:1234‐41. - PubMed
Czernichow 2006
    1. Czernichow S, Couthouis A, Bertrais S, Vergnaud A, Dauchet L, Galan P, Hercberg S. Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. American Journal of Clinical Nutrition 2006;84(2):395‐9. - PubMed
Dennert 2011
    1. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MPA, Horneber M. Selenium for preventing cancer. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858] - DOI - PMC - PubMed
Duffield 1999
    1. Duffield AJ, Thomson CD, Hill KE, et al. An estimation of selenium requirements for New Zealanders. American Journal of Clinical Nutrition 1999;70:896‐903. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple graphical test. BMJ 1997;315:629‐34. - PMC - PubMed
Fairweather 2011
    1. Fairweather‐Tait SJ, Bao Y, Broadley MR, Collings R, Ford D, Hesketh JE, Hurst R. Selenium in human health and disease. Antioxidants & Redox Signaling 2011;14:1337‐83. - PubMed
Flores‐Mateo 2006
    1. Flores‐Mateo G, Navas‐Acien A, Pastor‐Barriuso R, et al. Selenium and coronary heart disease: a meta‐analysis. American Journal of Clinical Nutrition 2006;84:762‐73. - PMC - PubMed
Freemantle 2001
    1. Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?. BMJ 2001;322:989‐91. - PMC - PubMed
Gao 2006
    1. Gao Y, Hannan NR, Wanyonyi S, Konstantopolous N, Pagnon J, Feng HC, et al. Activation of the selenoprotein SEPS1 gene expression by pro‐inflammatory cytokines in HepG2 cells. Cytokine 2006;33:246‐51. - PubMed
Hercberg 2004
    1. Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX study: a randomized, placebo‐controlled trial of the health effects of antioxidant vitamins and minerals. Archives of Internal Medicine 2004;164:2335‐42. - PubMed
Hercberg 2005
    1. Hercberg S, Bertrais S, Czernichow S, et al. Alterations of the lipid profile after 7.5 years of low‐dose antioxidant supplementation in the SU.VI.MAX Study. Lipids 2005;40:335‐42. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systmatic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org.
Hurst 2010
    1. Hurst R, Armah CN, Dainty JR, Hart DJ, Teucher B, Goldson AJ, et al. Establishing optimal selenium status: results of a randomized, double‐blind, placebo‐controlled trial. American Journal of Clinical Nutrition 2010;91:923‐31. - PMC - PubMed
Keshan Disease Research Group
    1. Keshan Disease Research Group. Observations on effect of sodium selenite in prevention of Keshan disease. Chinese Medical Journal 1979;92:471‐6. - PubMed
Korpela 1989
    1. Korpela H, Kumpulainen J, Jussila E, et al. Effect of selenium supplementation after acute myocardial infarction. Research Communications in Chemical Pathology and Pharmacology 1989;65:249‐52. - PubMed
Kuklinski 1994
    1. Kuklinski B, Weissenbacher E, Fahnrich A. Coenzyme Q10 and antioxidants in acute myocardial infarction. Molecular Aspects of Medicine 1994;15:S143‐7. - PubMed
Labunskyy 2011
    1. Labunskyy VM, Lee BC, Handy DE, Loscalzo J, Hatfield DL, Gladyshev VN. Both maximal expression of selenoproteins and selenoprotein deficiency can promote development of type 2 diabetes‐like phenotype in mice. Antioxidants & Redox Signaling 2011;14:2327‐36. - PMC - PubMed
Laclaustra 2009a
    1. Laclaustra M, Navas‐Acien A, Stranges S, Ordovas JM, Guallar E. Serum selenium levels and hypertension in the US population. Circulation, Cardiovascular Quality and Outcomes 2009;2:369‐76. - PMC - PubMed
Laclaustra 2009b
    1. Laclaustra M, Navas‐Acien A, Stranges S, Ordovas JM, Guallar E. Serum selenium concentrations and diabetes in US adults: National Health and Nutrition Examination Survey (NHANES) 2003‐2004. Environmental Health Perspectives 2009;117:1409‐13. - PMC - PubMed
Laclaustra 2010
    1. Laclaustra M, Stranges S, Navas‐Acien A, Ordovas JM, Guallar E. Serum selenium and plasma lipids in US adults: National Health and Nutrition Examination Survey (NHANES) 2003‐2004. Atherosclerosis 2010;210:643‐8. - PMC - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for Studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011.
Millen 2004
    1. Millen AE, Dodd KW, Subar AF. Use of vitamin, mineral, nonvitamin, and nonmineral supplements in the United States: The 1987, 1992, and 2000 National Health Interview Survey results. Journal of the American Dietetic Association 2004;104:942‐50. - PubMed
Mosca 2011
    1. Mosca L, Barrett‐Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 2011;124:2145‐54. - PMC - PubMed
Méplan 2007
    1. Méplan C, Crosley LK, Nicol F, Beckett GJ, Howie AF, Hill KE, et al. Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender‐specific manner (the SELGEN study). FASEB J 2007;21:3063‐74. - PubMed
Neve 1996
    1. Neve J. Selenium as a risk factor for cardiovascular diseases. Journal of Cardiovascular Risk 1996;3:42‐4. - PubMed
Papp 2007
    1. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxidants & Redox Signaling 2007;9:775‐806. - PubMed
Park 2012
    1. Park K, Rimm EB, Siscovick DS, Spiegelman D, Manson JE, Morris JS, et al. Toenail selenium and incidence of type 2 diabetes in US men and women. Diabetes Care 2012;35:1544‐51. - PMC - PubMed
Rayman 1997
    1. Rayman MP. Dietary selenium: time to act. BMJ 1997;314:387‐8. - PMC - PubMed
Rayman 2000
    1. Rayman MP. The importance of selenium to human health. Lancet. 2000;356:233‐41. - PubMed
Rayman 2009
    1. Rayman MP. Selenoproteins and human health: Insights from epidemiological data. Biochimica et Biophysica Acta 2009;1790:1533‐40. - PubMed
Rayman 2011
    1. Rayman MP, Stranges S, Griffin B, Pastor‐Barriuso R, Guallar E. Effect of supplementation with high‐selenium yeast on plasma lipids: a randomized, controlled trial. Annals of Internal Medicine 2011;154:656‐65. - PubMed
Rayman 2012
    1. Rayman MP. Selenium and human health. Lancet 2012;379:1256‐68. - PubMed
Salonen 1982
    1. Salonen JT, Alfthan G, Huttunen JK, Pikkarainen J, Puska P. Association between cardiovascular death and myocardial infarction and serum selenium in a matched‐pair longitudinal study. Lancet 1982;2:175‐9. - PubMed
Salonen 1988
    1. Salonen JT, Salonen R, Seppaenen K, Kantola M, Parviainen M, Alfthan G, et al. Relationship of serum selenium and antioxidants to plasma lipoproteins, platelet aggregability and prevalent ischemic heart disease in Eastern Finnish men. Atherosclerosis 1988;70:155‐65. - PubMed
Sattler 1994
    1. Sattler W, Maiorino M, Stocker R. Reduction of HDL‐and LDL‐associated cholesterylester and phospholipid hydroperoxides by phospholipid hydroperoxide glutathione peroxidase and Ebselen (PZ 51). Archives of Biochemistry and Biophysics 1994;309:214‐21. - PubMed
Stranges 2006
    1. Stranges S, Marshall JR, Trevisan M, Natarajan R, Donahue RP, Combs GF, et al. Effects of selenium supplementation on cardiovascular disease incidence and mortality: Secondary analyses in a randomized clinical trial. American Journal of Epidemiology 2006;163:694‐9. - PubMed
Stranges 2007
    1. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine 2007;147:217‐23. - PubMed
Stranges 2010a
    1. Stranges S, Navas‐Acien A, Rayman MP, Guallar E. Selenium status and cardio‐metabolic health: State of the evidence. Nutrition, Metabolism, and Cardiovascular Diseases 2010;20:754‐60. - PubMed
Stranges 2010b
    1. Stranges S, Laclaustra M, Ji C, Cappuccio FP, Navas‐Acien A, Ordovas JM, et al. High‐normal selenium status is associated with adverse lipid profile in British adults. Journal of Nutrition 2010;140:81‐7. - PMC - PubMed
Virtamo 1985
    1. Virtamo J, Valkeila E, Alfthan G, Punsar S, Huttunen JK, Karvonen MJ. Serum selenium and the risk of coronary heart disease and stroke. Am J Epidemiol. 1985;122:276‐82. - PubMed
Vunta 2007
    1. Vunta H, Davis F, Palempalli UD, Bhat D, Arner RJ, Thompson JT, et al. The anti‐inflammatory effects of selenium are mediated through 15‐deoxy‐{Delat} 12,14‐prostaglandin J2 in macrophages. Journal of Biological Chemistry 2007;282:17964‐73. - PubMed
Wei 2004
    1. Wei WQ, Abnet CC, Qiao YL, et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke and total death. American Journal of Clinical Nutrition 2004;79:80‐5. - PubMed
Whanger 1996
    1. Whanger P, Vendeland S, Park YC, Xia Y. Metabolism of sub‐toxic levels of selenium in animals and humans. Annals of Clinical and Laboratory Science 1996;26:99‐113. - PubMed
WHO 2003
    1. WHO Study Group. Diet, nutrition and the prevention of chronic diseases. World Health Organization, Geneva 2003; Vol. Report Series 916. - PubMed
WHO 2011
    1. Mendis S, Puska P, Norrving B editors. Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization, Geneva 2011.
Xia 2005
    1. Xia Y, Hill KE, Byrne DW, Xu J, Burk RF. Effectiveness of selenium supplements in a low selenium area of China. American Journal of Clinical Nutrition 2005;81:829‐34. - PubMed
Xia 2010
    1. Xia Y, Hill KE, Li P, Xu J, Zhou D, Motley AK, Wang L, et al. Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: a placebo‐controlled, double‐blind study of selenomethionine supplementation in selenium‐deficient Chinese subjects. American Journal of Clinical Nutrition 2010;92:525‐31. - PMC - PubMed
You 2001
    1. You WC, Chang YS, Heinrich J, et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S‐allyl cysteine levels, and toxicity. European Journal of Cancer Prevention 2001;10:257‐63. - PubMed
Zhang 2006
    1. Zhang L, Gail MH, Wang YQ, et al. A randomized factorial study of the effects of long‐term garlic and micronutrient supplementation and of 2‐wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition 2006;84:912‐9. - PubMed

Publication types